Corxel-Vincentage’s Oral GLP-1 Achieves Positive Phase II Obesity Trial Results

Obesity medicine is changing fast as companies work on making weight-loss pills instead of just shots. Corxel Pharmaceuticals and Vincentage Pharma recently shared great news about their new daily pill called CX11. This pill targets the same pathways as popular weight-loss injections but lets patients avoid needles entirely. Healthcare providers are watching this closely because an effective pill could make weight management much easier for many people.

Trial Design and Patient Population

The Phase II study included 246 adults to see how well the new pill works. Everyone in the study either had obesity or was overweight with at least one health issue linked to their weight. To keep the results fair and unbiased, the researchers set it up as a randomized, double-blind study. This means neither the doctors nor the patients knew who was getting the actual drug or a fake pill.

The researchers split the participants evenly into five different groups to test various options. Three groups took different strengths of CX11 with a slow build-up, while a fourth group took a high dose with a fast build-up. The last group took a placebo pill that contained no medicine at all. Everyone took their assigned pill once a day for 36 weeks so doctors could find the best dose.

Efficacy Outcomes and Weight Reduction

The new pill hit all its main goals across every single testing group. People taking the highest dose lost up to 11.5 percent of their total body weight by the end of the study. Even better, patients were still losing weight at the 36-week mark without hitting a plateau. This steady progress suggests that people might lose even more weight if they take the pill for a longer time.

These results mean CX11 can compete directly with the major weight-loss shots available today. Popular injections like Wegovy and Mounjaro have already proven that changing these gut hormones causes major weight loss. Now, this new data shows that a small pill can achieve similar success. Consequently, patients might soon get the same great results without dealing with weekly injections.

Dose Dependent Response Patterns

The results clearly showed that higher doses of the pill led to more weight loss. This pattern makes perfect sense given how these types of metabolic medicines work inside the body. The speed of the build-up also mattered, since a slower start helped prevent early side effects. These details will help doctors figure out the exact scheduling for the next big phase of testing.

Another study on the same drug looked at a separate group of patients over a longer timeline. In that 52-week trial, people taking the pill lost over 12 percent of their body weight. Meanwhile, the group taking the fake pill only lost about 1.3 percent of their weight. Looking at both studies together confirms that the pill gives a strong and reliable weight-loss signal.

Safety and Tolerability Profile

Most patients handled the daily pill quite well during the 36-week trial. Mild stomach issues were the most common side effects reported by the participants. Around 33 percent of people felt some nausea, and a small number experienced brief vomiting or diarrhea. These tracking numbers are very normal and look identical to the side effects seen with current weight-loss shots.

Adverse Event	Incidence Rate Across Active Arms
Nausea	33% – 34%
Vomiting	12% – 16%
Diarrhea	4% – 12%
Constipation	2% – 12%

Very few people dropped out of the study, which proves the pill is easy to live with. Doctors also checked liver health closely and found zero signs of any danger. This is excellent news because over 1,500 people have now taken this drug across different trials without liver issues. Because of this clean track record, the safety profile looks strong and steady.

Clinical context within the oral GLP-1 landscape

The push for weight-loss pills has gained massive speed in the medical world lately. While current injections work wonders for weight loss and blood sugar, many people truly hate needles. Shots also require cold fridge storage and can be annoying to travel with or use. A simple pill solves all these problems while being much cheaper and faster to manufacture in large amounts.

Several other pharmaceutical companies are working on their own weight-loss pills right now. A few of these rival medicines are already showing decent weight-loss percentages in early tests. This crowded market shows why the positive data for CX11 is such a big deal. The industry is clearly shifting toward convenient pills that can match the power of traditional shots.

There is a huge difference in how pills and shots are made behind the scenes. Simple pills are much easier to produce in factories, which naturally lowers the total cost. Plus, pills can sit on regular shelves without needing ice packs or refrigerated shipping trucks. As a result, these oral medicines could easily reach rural clinics and communities with limited resources.

Implications for Global Phase III Development

Thanks to these positive results, the company is moving CX11 into final Phase III trials. They also plan to test the pill specifically on patients living with type 2 diabetes. To fund these massive global studies, Corxel raised 287 million USD in fresh backing. This massive investment proves that modern investors have high confidence in oral weight-loss tools.

Corxel bought the global rights to this compound back in late 2024. This partnership allows them to run trials and collect data in multiple areas at the same time. Combining all this data gives doctors a much clearer picture of how the medicine performs. Federal regulatory agencies will review all these files together before deciding to approve the pill for public use.

With these Phase II results finished, CX11 is entering the final testing stretch with great momentum. Doctors who treat obesity should watch the upcoming data updates very carefully. Ultimately, the way we treat weight management will change forever if a daily pill gets official approval.

Conclusion 

The early data for CX11 builds a strong foundation before the final large-scale trials begin. Losing 11.5 percent of body weight while staying safe and manageable is a major win. Data from the parallel studies adds even more confidence to how this medicine works. Together, these facts show that weight-loss pills are ready to become a true alternative to shots.

As the next phase of testing rolls out, the medical community will learn about long-term success rates. Positive results from these final trials could open up fresh options for millions of people. Swapping a needle for a daily pill might finally solve the biggest hurdles in long-term weight care. Continued testing through careful studies remains the best way to prove this pill can deliver on its promises.

References

Clinical Trials Arena. (2026, May 19). Vincentage Pharma touts Phase III win for oral GLP-1RA. Clinical Trials Arena. https://www.clinicaltrialsarena.com/news/vincentage-pharma-touts-phase-iii-win-for-oral-glp-1ra/

Clinical Trials Arena. (2026, June 24). Corxel to advance oral obesity drug to Phase III trials. Clinical Trials Arena. https://www.clinicaltrialsarena.com/news/corxel-to-advance-oral-obesity-drug-to-phase-iii-trials/

Corxel Pharmaceuticals Limited. (2026, June 23). Corxel Pharmaceuticals reports positive top-line results from Phase 2 trial of CX11 in obese and overweight U.S. adults [Press release]. GlobeNewswire via Yahoo Finance. https://finance.yahoo.com/healthcare/articles/corxel-pharmaceuticals-reports-positive-top-120000068.html

Fierce Biotech. (2026, January 22). Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug. Fierce Biotech. https://www.fiercebiotech.com/biotech/corxel-secures-287m-fund-phase-23-obesity-studies-oral-glp-1-drug

Kansteiner, F. (2026, June 24). Corxel gears up for global pivotal push after oral GLP-1 posts ‘competitive’ ph. 2 results. Fierce Biotech. https://www.fiercebiotech.com/biotech/corxel-gears-global-pivotal-push-after-oral-glp-1-posts-competitive-ph-2-results

FirstWord Pharma. (2026, June 24). Corxel charts global pivotal push as oral GLP-1 succeeds in US study. FirstWord Pharma. https://firstwordpharma.com/story/7644150

HCPLive. (2026, June 24). CX11 shows weight loss in Phase 2 obesity trial, Corxel reports. HCPLive. https://www.hcplive.com/view/cx11-shows-weight-loss-in-phase-2-obesity-trial-corxel-reports

BioWorld. (2026, June 24). Corxel-Vincentage’s oral GLP-1 meets phase II obesity endpoints. BioWorld. https://www.bioworld.com/articles/732050-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints